Nefiracetam

Nefiracetam (DM-9384, Translon), the N-(2,6-dimethylphenyl) acetamide derivative of 2-oxopyrrolidine and the most pharmacologically characterized fat-soluble member of the racetam nootropic class, is a cognition-enhancing agent developed by Daiichi Pharmaceutical (now Daiichi Sankyo) in Japan during the 1980s for the treatment of cognitive impairment secondary to cerebrovascular disease. Unlike the parent compound piracetam, which acts principally through membrane fluidity modulation and non-specific cholinergic facilitation, nefiracetam engages a convergent set of molecular targets: high-affinity interaction with the GABA-A receptor chloride channel complex (IC50 approximately 8.5 nM for displacement of [3H]muscimol binding), potentiation of neuronal nicotinic acetylcholine receptor currents through a G-protein-coupled protein kinase C pathway, enhancement of voltage-gated L-type and N-type calcium channel currents, potentiation of NMDA receptor function via protein kinase C activation with consequent reduction of the voltage-dependent magnesium block, and facilitation of hippocampal long-term potentiation through CaM kinase II and protein kinase C alpha activation downstream of NMDA receptor and metabotropic glutamate receptor 5 stimulation. The composite pharmacology produces a sustained facilitation of hippocampal synaptic transmission that resembles long-term potentiation and that depends on presynaptic nicotinic acetylcholine receptor activation and consequent glutamate release.

Pharmacokinetics in healthy human volunteers are characterized by rapid oral absorption with peak plasma concentrations at approximately 1 to 2 hours, monophasic elimination with a plasma half-life of 3 to 5 hours, linear dose-proportional kinetics across the 100 to 900 mg range, negligible accumulation on repeated dosing, and principal hepatic metabolism through CYP3A4-mediated 5-hydroxylation of the pyrrolidine ring with a minor contribution from CYP1A2. Less than 10 percent of the administered dose is excreted unchanged in urine. The compound crosses the blood-brain barrier readily owing to its lipophilicity relative to piracetam.

The clinical development program encompassed three principal indications. In cerebrovascular dementia, Phase 2 and Phase 3 trials conducted in Japan by Daiichi demonstrated cognitive improvement in patients with sequelae of cerebral infarction; however, a revised Phase 3 trial failed to meet its primary endpoint, and the New Drug Application was withdrawn in Japan in February 2002. In Alzheimer’s disease, the National Institute of Neurological Disorders and Stroke sponsored a randomized, double-blind, placebo-controlled Phase 2 trial (NCT00001933) evaluating nefiracetam at 600 mg and 900 mg daily for 20 weeks; preliminary reports indicated dose-dependent cognitive improvement in a subset of patients, but the program was not advanced to Phase 3. In poststroke depression and apathy, Robinson et al. (2008, 2009) conducted randomized controlled trials demonstrating that nefiracetam at 900 mg daily produced significant reduction in apathy scores in poststroke depressed patients, though the primary depression endpoint was not met; a subsequent confirmatory trial by Starkstein et al. (2016) for poststroke apathy did not replicate the benefit, possibly owing to insufficient statistical power.

The compound is not approved in any jurisdiction as of the current monograph date. It is available as a research-grade preparation from multiple chemical suppliers. The principal preclinical toxicology concern is species-specific nephrotoxicity observed in dogs and rats attributable to a metabolite (M-18) that is not formed in humans or primates; long-term studies in humans and primates have not identified renal toxicity. This monograph reviews the chemistry, synthesis, and structural positioning of nefiracetam; the multi-target molecular pharmacology in mechanistic detail; the human pharmacokinetic record; the preclinical pharmacology across cognitive, anticonvulsant, and neuroprotective models; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a structured comparative assessment of five racetam-class nootropics against nefiracetam on five competency standards.